Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP) announced its earnings results on Monday. The company reported ($2.89) earnings per share for the quarter, missing the consensus estimate of ($2.39) by ($0.50), FiscalAI reports. Tonix Pharmaceuticals had a negative return on equity of 68.99% and a negative net margin of 548.64%. The company had revenue of $17.23 million for the quarter, compared to analysts’ expectations of $16.32 million.

Here are the key takeaways from Tonix Pharmaceuticals’ conference call:

• TONMYA sales and prescriptions grew: Third-quarter net sales were approximately $15 million, up 37% quarter-over-quarter, while prescriptions rose 28% to 16,375. Management attributed momentum to payer agreements, improved prescription approvals and the expanded 150-person sales force, and said early fourth-quarter trends were continuing.
• TONMYA coverage reached approximately 53% of U.S. covered lives, and the company reported rising refill prescriptions and declining bridge-script reliance. Management said the expanded sales force is reaching a larger share of fibromyalgia prescribers and expects broader access and awareness to support growth.
• Dr. Reddy’s filed a Paragraph IV ANDA challenging TONMYA patents; Tonix said it will defend its intellectual property, which it says currently provides protection into 2034. The company did not provide details on the litigation’s timing or likely outcome.
• Tonix ended September with $162.8 million in cash, down from $207.6 million at year-end, and said cash plus post-quarter equity-offering proceeds should fund operations into early Q3 2027. Quarterly R&D expenses rose to $25.8 million and SG&A to $45.6 million, largely reflecting pipeline development and TONMYA launch costs.
• The company is advancing its pipeline: the HORIZON phase II MDD study is enrolling, the TNX-4800 Lyme-prevention field study is planned to start in 2027, and an investigator-led TNX-1500 kidney-transplant study is expected to begin in early 2027. These programs remain clinical-stage and their timing and outcomes are uncertain.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock opened at $4.49 on Tuesday. The stock has a market capitalization of $77.00 million, a price-to-earnings ratio of -0.35 and a beta of 1.90. The business has a 50-day moving average of $8.53 and a 200 day moving average of $12.14. Tonix Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $20.56.

Key Headlines Impacting Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: TONMYA generated approximately $15 million in third-quarter net sales, up 37% from the second quarter. The company cited broader payer coverage and expanded sales reach, while total revenue of $17.23 million also topped analysts’ $16.32 million estimate. Tonix third-quarter results
• Neutral Sentiment: Tonix had approximately $163 million in cash and cash equivalents at quarter-end, with reports indicating its cash runway extends into early Q3 2027. That provides funding for commercial growth and clinical programs, but also highlights the need to manage cash as the company continues to incur losses. Q3 earnings call highlights
• Negative Sentiment: Third-quarter EPS was a loss of $2.89, worse than the $2.39 loss analysts expected; coverage also pointed to higher costs and a wider loss. A Dr. Reddy’s patent challenge to TONMYA adds uncertainty around the product’s growth prospects. These concerns help explain pressure on TNXP shares despite the sales growth. Q3 loss and shares report

Insider Transactions at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 2,000 shares of Tonix Pharmaceuticals stock in a transaction dated Thursday, August 27th. The shares were acquired at an average price of $13.79 per share, with a total value of $27,580.00. Following the completion of the transaction, the chief executive officer owned 11,005 shares of the company’s stock, valued at $151,758.95. This trade represents a 22.21% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TNXP. Raymond James Financial restated a “strong-buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Canaccord Genuity Group began coverage on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. They set a “buy” rating and a $18.00 price objective for the company. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, October 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $22.33.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving the central nervous system, immunology and infectious diseases. The company’s research programs are designed to address disorders with significant unmet medical needs, including chronic pain, neuropsychiatric conditions and infectious diseases.

Tonix’s pipeline has included TNX-102 SL, an investigational sublingual formulation of cyclobenzaprine being studied for fibromyalgia and other pain-related conditions.